This program is not affiliated with Digestive Disease Week®. Sunday, May 19, 2019 Continuing Medical Education Breakfast Activity
6:00 AM - 7:30 AM PT
Manchester Grand Hyatt Seaport Ballroom FGH 1 Market Place San Diego, CA
5:30 AM – 6:00 AM
Registration and Breakfast
6:00 AM – 6:10 AM
Welcome Parambir Dulai, MD
6:10 AM – 6:25 AM
Burden of Suboptimal Management of IBD William J. Sandborn, MD
6:25 AM – 6:35 AM
6:35 AM – 6:50 AM
Assessment of Disease Prognosis and Severity in Guiding Treatment Decisions Marla C. Dubinsky, MD
6:50 AM – 7:00 AM
7:00 AM – 7:10 AM
Selecting the Right Biologic for the Right Patient Parambir Dulai, MD
7:10 AM – 7:20 AM
7:20 AM – 7:30 AM
Closing Remarks Parambir Dulai, MD
Parambir Dulai, MD (Chair) Assistant Professor
UC San Diego School of Medicine
La Jolla, CA
Marla C. Dubinsky, MD Professor, Pediatrics and Medicine Chief, Pediatric Gastroenterology and Nutrition Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Icahn School of Medicine, Mount Sinai Hospital
New York, NY
William J. Sandborn, MD Professor, Medicine and Adjunct Professor, Surgery Chief, Division of Gastroenterology Vice Chair, Clinical Operations, Department of Medicine Director, UCSD IBD Center, UC San Diego Health System
La Jolla, CA
This session integrates current evidence-based insights and patient case challenges through a series of expert panel discussions, with an emphasis on new data that direct biologic treatment selection, as well as new treatment decision tools.
TARGET AUDIENCE Gastroenterology physicians, NPs, and PAs who encounter and manage patients with inflammatory bowel disease (IBD).
LEARNING OBJECTIVES After this symposium, you should be better able to:
Apply novel, predictive, decision support tools to stratify patients with inflammatory bowel disease (IBD) based on complication risk and disease severity in order to inform appropriate treatment initiation and timing
Integrate biologics into the treatment regimen for IBD based on individual probability of response to specific biologics
Identify patients with IBD being treated with biologics who require more aggressive treatment approaches, such as combination therapy and treat-to-target monitoring
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
There is no fee for this educational activity.
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact RMEI prior to the live event at (866) 770-RMEI.
STATEMENT OF SUPPORT
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Additional educational activities offered by RMEI Medical Education, LLC can be found
at www.RMEI.com or by calling toll-free (866) 770-RMEI.